P-HTM-04-Protocol LAL (5)-Sef.lucr.Dr.Andreea Moicean - SRH
P-HTM-04-Protocol LAL (5)-Sef.lucr.Dr.Andreea Moicean - SRH
P-HTM-04-Protocol LAL (5)-Sef.lucr.Dr.Andreea Moicean - SRH
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
- VP16 60 mg/mp i.v.la sfarsitul cladribinei zilele 1 – 5<br />
- Cytarabina 1,5g/mp i.v.(90 min) la 4 ore de la VP16 zilele 1 – 5<br />
(1 g/mp > 55 ani)<br />
- G-CSF 5 microg/kg s.c. din ziua 6<br />
Profilaxia SNC (idem CONSOLIDAREA I) ziua 1<br />
(tripla)<br />
C. Pacientii cu <strong>LAL</strong> risc foarte inalt<br />
De la inceputul celei de-a II-a inductii sunt tratati cu chimioterapie (similara<br />
grupului cu risc inalt) si Imatinib pana la TCSH. Dupa TCSH Imatinib-ul se<br />
continua in functie de BMR.<br />
12
Change language